ArticleFrontiers in immunology2025
Expression and correlation of SOCS3 and Eotaxin mRNA and proteins levels in nasal mucosal tissue of allergic rhinitis patients.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- UC-MSCs-derived exosomal circFOXP1 alleviates allergic rhinitis through EZH2/EGR1/Blimp-1 axis.Respiratory research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to investigate the expression and interaction mechanisms of Suppressor of Cytokine Signaling 3 (SOCS3) and Eotaxin in the nasal mucosal tissues of patients with Allergic Rhinitis (AR). Methods: In this retrospective study, we selected nasal mucosa tissues from 35 AR patients as the AR group, and nasal mucosa tissues from 22 patients with isolated nasal septum deviation as the control group. Utilizing reverse transcription polymerase chain reaction (RT-PCR) techniques, we measured the expression levels of SOCS3 mRNA and Eotaxin mRNA in both groups. Additionally, immunohistochemical methods were employed to assess the protein expression of SOCS3 and Eotaxin in these tissues. Results: The average optical density value of SOCS3 protein in the AR group was 0.270 ± 0.05, significantly higher than 0.160 ± 0.04 in the control group (P<0.01); the average optical density value of Eotaxin protein in the AR group was 0.240 ± 0.04, also significantly higher than 0.164 ± 0.03 in the control group (P<0.01). At the mRNA level, the ratio of SOCS3 mRNA to GAPDH in the AR group was 0.83 ± 0.27, and the ratio of Eotaxin mRNA to GAPDH was 0.71 ± 0.21, both significantly higher than 0.32 ± 0.11 and 0.22 ± 0.08 in the control group. Besides, the expression levels of SOCS3 protein and mRNA in the nasal mucosal tissues of AR patients were positively correlated with the expression of Eotaxin protein and mRNA (r=0.927, P<0.01; r=0.854, P<0.01). Conclusion: The high expression of SOCS3 and Eotaxin in the nasal mucosal tissues of AR, as well as the positive correlation between them, suggest that they may play an important role in the pathogenesis of AR. This study provides new experimental evidence for in-depth understanding of the pathogenesis of AR and new potential targets for the treatment of AR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.